Compare VNOM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNOM | SYRE |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.7B |
| IPO Year | 2025 | 2015 |
| Metric | VNOM | SYRE |
|---|---|---|
| Price | $39.94 | $94.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 18 |
| Target Price | $55.45 | ★ $123.87 |
| AVG Volume (30 Days) | ★ 2.0M | 823.0K |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,395,000,000.00 | N/A |
| Revenue This Year | $92.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.97 | ★ N/A |
| Revenue Growth | ★ 62.02 | N/A |
| 52 Week Low | $35.27 | $24.58 |
| 52 Week High | $51.13 | $110.64 |
| Indicator | VNOM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 46.80 |
| Support Level | N/A | $93.28 |
| Resistance Level | $45.45 | $105.94 |
| Average True Range (ATR) | 1.37 | 5.92 |
| MACD | -0.29 | -1.13 |
| Stochastic Oscillator | 7.99 | 7.83 |
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.